HCW Biologics Secures Additional U.S. Patents for Alopecia Treatment

Biotechnology firm HCW Biologics has strengthened its intellectual property portfolio by securing additional U.S. patents for HCW9302, a clinical-stage immunotherapeutic targeting alopecia areata.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

taiwan-newsCatalan1d ago

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - Taiwan News

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment Taiwan News

Read full article →

HCW Biologics Secures Additional U.S. Patents for Alopecia Treatment

Sources

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - Taiwan News

Related Stories

Retired IAF Pilot Abhinandan Varthaman Joins Commercial Airline After Service

App Developers Launch $2.7 Billion Lawsuit Against Apple in UK

Nscale touts $103 billion contracted revenue ahead of potential IPO, The Information reports

Snowflake Shares Surge on AI-Driven Earnings Beat and Raised Guidance